Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

In An Updated Analysis From Phase 3 NATALEE Trial Of Novartis' Kisqali (Ribociclib) Added To Endocrine Therapy Shows Deepening Benefit Beyond Three-year Treatment Period, Reducing Risk Of Recurrence By 28.5%, Compared To ET Alone, For Stage II And III Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer

Author: Benzinga Newsdesk | September 16, 2024 04:33am

Posted In: NVS